On May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a ...

The American Diabetes Association’s annual conference kicks off amid a dynamic year for diabetes tech, as access improves for ...

Experts speaking at the ADA’s Scientific Sessions supported making CGMs more accessible, but debated their usefulness for ...

The evolution of diabetes technologies has led to the expansion of automated insulin delivery for type 2 diabetes, continuous ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...

With Medtronic’s new insulin sensor receiving FDA approval last month and its Abbott-based sensor now submitted for clearance, the diabetes business plans to bring two new continuous glucose ...

The Diabetes Devices Market was valued at US$ 33.4 Billion in 2024 and is projected to reach US$ 64.8 Billion by 2033, growing at a CAGR of 7.7%. The U.S. diabetes devices market is witnessing strong ...

Leading firms like Medtronic, Insulet Corporation, Tandem Diabetes Care, and Dexcom dominate the scene, each bringing unique strengths to the table. Medtronic, for instance, offers the MiniMed 670G ...

DexCom DXCM delivered robust first-quarter 2025 results, underpinned by strong category demand, record new patient growth and ...

For many, a partnership between Abbott and Medtronic, two medtech giants and frequent competitors, would have seemed unlikely ...

BTIG analysts said today that MiniMed, the Medtronic diabetes business, has some significant pipeline updates.

Ethical approval for this study has been granted by Sunderland Research Ethics Committee (09/H0904/63) and Clinical Trial Authorisation has been given by the Medicines and Healthcare products ...